Evidence Vault

Executive Summary: Converging Regulation and ReimbursementThe traditional paradigm of healthcare innovation—a linear progression from bench to bedside—is fundamentally incompatible with the iterative nature of digital health. Historically, medical device manufacturers have faced a "chicken-and-egg" dilemma: they require real-world outcomes data to secure regulatory clearance and payer uptake, but they cannot generate that data without the very clearance and reimbursement they seek. In 2026, the federal government has addressed this structural gridlock through the coordinated launch of the Centers for Medicare & Medicaid Services (CMS) Advancing Chronic Care with Effective, Scalable Solutions (ACCESS) model and the Food and Drug Administration (FDA) Technology-Enabled Meaningful Patient Outcomes (TEMPO) pilot. By aligning payment incentives with regulatory flexibility, these programs create a synergistic loop that allows digital health tools to enter the clinical workflow sooner, generating the high-trust evidence required for both long-term solvency and market authorization. CMS ACCESS: The Demand-Side Reimbursement CatalystLaunching on July 5, 2026, the ACCESS model represents a ten-year national test of an alternative payment methodology designed to replace episodic fee-for-service (FFS) with Outcome-Aligned Payments (OAPs).Mechanics of Outcome-Aligned PaymentsUnder ACCESS, Medicare Part B providers receive fixed, recurring payments for the continuous management of beneficiaries with chronic conditions.Payment Structure: Participating organizations receive up to 50% of the total OAP in upfront installments to support the operational costs of technology-enabled care. The remaining 50% is withheld and subject to reconciliation based on clinical performance.Performance Metrics: Payments are tied to "Outcome Attainment Rates"—the percentage of a patient panel that meets specific, guideline-informed targets compared to each patient's unique baseline.Focus Areas: The model initially targets four high-prevalence clinical tracks: Early Cardio-Kidney-Metabolic (eCKM), Cardio-Kidney-Metabolic (CKM), Musculoskeletal (MSK), and Behavioral Health (BH).By rewarding clinical results rather than service volume, ACCESS creates a direct financial incentive for providers to adopt digital therapeutics (DTx), remote patient monitoring (RPM), and wearable devices that can drive measurable physiological changes. FDA TEMPO: The Regulatory Supply SandboxRecognizing that digital health devices often improve through rapid iteration in real-life settings, the FDA’s Center for Devices and Radiological Health (CDRH) launched the TEMPO pilot as a voluntary "regulatory sandbox".Enforcement Discretion and Real-World EvidenceTEMPO allows selected U.S.-based manufacturers of digital health tools to deploy their devices within ACCESS-participating organizations before obtaining full 510(k) or De Novo marketing authorization.Regulatory Flexibility: The FDA may exercise "enforcement discretion" for certain premarket and investigational device requirements, provided the device is used under clinician supervision and meets strict safety guardrails.Structured Data Collection: In exchange for earlier market entry, manufacturers must commit to sharing real-world data (RWD) with the FDA. This data is used to generate the Real-World Evidence (RWE) necessary to support future formal marketing submissions.Iterative Discussions: The pilot utilizes "sprint" discussions—focused interactions aimed at reaching agreement on endpoints and analysis plans within defined timelines (typically 45 days)—leveraging the framework of the Total Product Life Cycle Advisory Program (TAP).The Synergistic Loop: Breaking the Innovation BarrierThe true strategic value for healthcare executives lies in the interplay between these two programs. The alignment of ACCESS and TEMPO eliminates the historical gap between regulatory clearance and reimbursement.Reimbursement Demand: The ACCESS model creates a cohort of providers who are financially motivated to use technologies that reduce biomarkers (like HbA1c or blood pressure) or improve functional outcomes.Regulatory Supply: The TEMPO pilot provides a pathway for manufacturers to supply these clinicians with tools that are not yet cleared but are clinically promising.High-Trust Evidence Generation: Clinicians test clinical hypotheses in the context of "everyday" practice. The data generated serves a dual purpose: it fulfills the clinical outcome reporting requirements for CMS payment reconciliation and provides the FDA with the real-world performance data needed for authorization.Market Advantage: Companies participating in the synergistic loop gain a multi-year lead over competitors trapped in the traditional, slow RCT-to-reimbursement cycle. Clinical Tracks and Outcome TargetsThe synergy is most potent in clinical areas where technology can bridge the gap between physician visits.Technical Mechanics: Interoperability and ConsentTo ensure the integrity of the synergistic loop, the models mandate high standards for data architecture and patient protection.Mandatory Interoperability: ACCESS participants must share standardized clinical updates electronically through FHIR®-based APIs or Health Information Exchanges (HIEs). This ensures that "ground truth" clinical data flows seamlessly to primary care practitioners (PCPs) and regulators.Enhanced Beneficiary Consent: Providers using TEMPO devices must obtain specific consent from patients, informing them that the device is part of an FDA pilot and that their data will be shared with the agency for performance monitoring.Co-Management Incentives: To prevent care fragmentation, CMS offers a new co-management payment (approximately $30 per use) to PCPs who review and coordinate care updates from ACCESS participants. Strategic Implications for ExecutivesFor healthcare leaders, the ACCESS-TEMPO alignment necessitates a shift in organizational strategy:For MedTech Manufacturers: Transition from seeking "clearance first" to seeking "pilot partnership". The ability to generate RWE while simultaneously earning revenue via ACCESS-participating partners is a significant de-risking event for investors.For Provider Organizations (MSOs): The 50% performance withhold in ACCESS creates a substantial reconciliation risk. To mitigate this, MSOs must adopt high-fidelity tracking tools that provide real-time visibility into whether a patient is hitting their outcome targets before the reconciliation window closes.For Payers and Self-Insured Employers: These models provide a framework for evaluating digital health tools based on actual "Substitute Spend" reduction (e.g., fewer ER visits or delayed surgeries) rather than theoretical benefit. ConclusionThe alignment of CMS ACCESS and FDA TEMPO signals the end of "proxy-based" healthcare. In this new era, market advantage is secured not by those who perform the most procedures, but by those who can provide verifiable, technology-enabled proof of clinical success. By entering the synergistic loop, healthcare stakeholders can transform clinical encounters into high-trust datasets, driving both patient health and business valuation in the 2026 regulatory environment.

Executive Summary: The End of the Proxy EraAs of early 2026, the American healthcare system has reached a critical inflection point in the validation of clinical efficacy and safety. For decades, the industry relied on "administrative proxies"—billing codes, claims data, and retrospective audits—to approximate population health and provider performance. However, a structural transition toward Proven Medical Accuracy is underway, derived directly from the point of care. This shift represents a fundamental realignment of the healthcare economy, where the data generated by a clinical encounter is as vital an asset as the treatment itself.The Systemic Failure of Legacy CodingThe reliance on legacy fee-for-service (FFS) reimbursement models and administrative data architecture has historically created a significant "veracity gap."Limitations of ICD-10 and HCPCS: While ICD-10-CM codes provide classification, they often act as mere proxies for a patient’s actual clinical state. The 2026 updates to ICD-10-CM, including nearly 75,000 codes, highlight an increasing but often overwhelming granularity that still struggles to capture real-time clinical nuances without high-fidelity documentation [1].Coding Discrepancies: These codes are frequently influenced by documentation nuances and financial incentives rather than pure clinical signals. Common errors such as unbundling or upcoding continue to distort the accuracy of claims-based data [2].The "Veracity Gap" in Audits: Traditional administrative datasets often lack the granularity required for high-stakes clinical decision-making or rigorous federal audits. Historical reliance on these proxies has led to compliance risks when documentation does not perfectly align with the reported codes [1, 3].Administrative Bottlenecks: Legacy systems require vast volumes of manual paperwork, deterring the collection of high-fidelity, longitudinal data and creating a bottleneck that AI agents are now being deployed to solve [4].The CMS Shift: Data Accuracy as Revenue DefenseIn 2026, the Centers for Medicare & Medicaid Services (CMS) has altered its enforcement stance, shifting from a focus on "effort" to a focus on "proof."The Removal of Traditional Audit ScoringCMS is moving toward binary standards focused on immediate impact and remediation. If internal data does not reconcile with federal "sources of truth," such as the Provider Enrollment, Chain, and Ownership System (PECOS), organizations face immediate revenue consequences rather than incremental score deductions [1, 5].Automated Oversight and AIThe agency is increasingly utilizing advanced analytics and artificial intelligence to identify safety and efficacy signals in real-time. This proactive approach allows auditors to identify non-compliance and data anomalies before a provider even recognizes the error [1, 4].Outcome-Aligned Payments (OAP)Central to this mandate is the launch of the Advancing Chronic Care with Effective, Scalable Solutions (ACCESS) model. Scheduled to begin July 1, 2026, this 10-year national test focuses on beneficiaries with chronic conditions like hypertension, diabetes, and chronic musculoskeletal pain [6]. Unlike traditional FFS, ACCESS provides recurring payments explicitly tied to achieving measurable, guideline-informed health outcomes against each patient's own baseline [7].From Billing Codes to Proven Medical AccuracyThe transition to Proven Medical Accuracy requires capturing high-trust evidence as a byproduct of care rather than as an administrative afterthought.Point-of-Care Data Integrity: High-fidelity datasets must meet new regulatory and reimbursement requirements for medical accuracy. This is particularly vital in new models where payment is tied directly to clinical results rather than service volume [6, 7].Role of Interoperability: Mandates for FHIR®-based APIs ensure that high-accuracy data flows seamlessly between participants, reducing the friction previously inherent in data exchange [8].Audit-Ready Ground Truth: To survive in a binary audit environment, organizations must maintain an "audit-ready" ground truth that is verifiable and free from the artifacts of legacy coding practices [1, 5].Strategic Implications for Healthcare ExecutivesThe 2026 Veracity Mandate demands a total re-evaluation of data strategy and operational governance.Reclassify as a Tech-Enabled Asset: Organizations that can provide verified clinical veracity can shift from "service business" valuations to higher tech-enabled asset multiples by proving outcomes with data-driven precision [7, 8].Establish Strict Internal Reporting: Compliance is no longer a soft target; practice locations, ownership, and clinical outcomes must be reconciled within strict non-negotiable windows to avoid revenue stoppages [1, 5].Invest in Explainable AI: As AI becomes integrated into operations, executives must demand "explainability" to defend decisions during federal scrutiny and mitigate liability risks [4].Prioritize Quality Over Volume: ACCESS incentives reward specialists who detect worsening conditions early and use technology to prove functional recovery rather than those who simply increase procedural volume [6, 7].ConclusionThe 2026 Veracity Mandate is an opportunity for the medical profession to re-establish primary authority through verifiable proof. By moving beyond administrative proxies and embracing proven medical accuracy, leaders can safeguard revenue, reduce liability, and drive higher business valuations in an increasingly transparent global market.

The PremiseModern biomedicine is awash in correlations. High-throughput assays, EHR exhaust, and observational registries generate torrents of associations linking exposures to outcomes. These signals are cheap to produce and easy to publish. Yet clinical action requires something harder: causal understanding. When we mistake correlation for cause, we translate statistical noise into medical advice, inflate hope, and waste scarce clinical attention. The problem is not that correlations are useless; it is that they are increasingly treated as sufficient.The DistortionCorrelation masquerades as causation through three recurrent pathways:Confounding and selection. Patients self-select into treatments; clinicians allocate therapies based on prognosis; healthier people seek screening. Unmeasured factors drive both exposure and outcome, creating spurious links. Without a causal design—clear counterfactuals, exchangeability, and temporality—associations reflect the clinic’s sorting mechanism more than biology.Surrogate bias. We optimize for variables that are measurable (biomarkers, intermediate endpoints) rather than variables that matter (morbidity, mortality, function). Surrogates correlate with outcomes in one context and fail in another, inviting ineffective or harmful interventions that “improve the number” while leaving patients unchanged.Flexible analysis and garden-of-forking-paths. When thousands of features meet dozens of modeling choices, some association will appear significant. Absent prespecified analyses, causal graphs, and sensitivity checks, correlation is a by-product of researcher degrees of freedom, not the world.Together, these distortions reward speed over design. They generate publishable patterns that crumble at the bedside because they never answered a causal question in the first place. The ConsequenceThe mirage of correlation has practical and moral costs:Therapeutic misdirection. Interventions built on non-causal signals underperform in trials or succeed on surrogates while failing on outcomes, exposing patients to cost and risk without benefit.Policy volatility. Public guidance oscillates with each new association study, eroding trust among clinicians and citizens who experience “whiplash science.”Equity harms. Spurious correlations often encode structural confounding (access, environment, bias). Acting on them can amplify disparities by directing resources toward populations easiest to measure rather than those most likely to benefit.Epistemic stagnation. When correlations are treated as answers, we stop asking mechanistic questions. Biology becomes a backdrop for analytics rather than the governor of inference.In short, correlation without design produces abundant signals but little understanding—a surplus of claims and a deficit of care.The Way ForwardRestoring causation requires redesign, not rhetoric:Start with a target trial. In observational settings, explicitly specify the randomized trial you wish you could run: eligibility, treatment strategies, time zero, assignment, outcomes, follow-up, and causal contrasts. Then emulate it with appropriate data and methods.Draw the causal graph. Make assumptions visible with directed acyclic graphs (DAGs). Identify confounders to adjust, colliders to avoid, mediators to preserve, and instruments to employ. Method follows model.Commit to temporality and specification. Define exposures and outcomes prospectively where possible; preregister analytic plans; limit researcher degrees of freedom; conduct sensitivity analyses (negative controls, E-values, falsification endpoints).Retire weak surrogates. Tie intermediate markers to outcomes through validated causal pathways—or prioritize trials and longitudinal endpoints that capture what patients value.Report counterfactuals, not just correlations. Express results as effects under interventions (“If assigned strategy A vs B…”) and disclose the assumptions under which these effects are identified.Integrate mechanism. Let biology constrain models. Use causal reasoning to decide what must be true for an effect to exist, and design studies that could prove it false.Correlation is a starting line, not a finish. Medicine earns trust when we move from signals to causes—because only causes tell us what to do.

The Old Asymmetry For generations, medicine has depended on the generosity of its subjects and the ambition of its scientists. Patients provide their stories and samples; researchers extract discoveries. Yet when value emerges — in patents, data sales, or institutional prestige — the contributors of truth are absent from the ledger.This asymmetry is not accidental; it is architectural. Systems that cannot trace consent cannot distribute benefit.Circle’s model rewrites this architecture. It restores value to its rightful origin — to the individuals whose verifiable experiences sustain the science itself.The Economics of AcknowledgmentOwnership begins with recognition. Without acknowledgment, participation becomes exploitation disguised as progress.In the Circle ecosystem, every patient’s verified contribution is recorded, preserved, and auditable. Each act of consent, each update of data, generates a measurable stake in the moral economy of truth. This is not symbolic gratitude; it is computable recognition.The data contributor becomes a partner, not a product.Value as ReciprocityIn moral philosophy, reciprocity sustains justice: one good act should invite another. Circle turns this into mechanism. Each verified dataset generates a return proportional to its integrity, depth, and longevity. The more completely and ethically one participates, the greater the reward.This is not charity but reciprocal economics — a system where moral equity yields material equity.From Subjects to StakeholdersTraditional research treats patients as data sources, dissolving their agency at the moment of contribution. Circle’s token model ensures that agency persists. Participants remain visible in every subsequent use of their data through immutable provenance. Their involvement continues not as memory, but as stake.This transforms medicine from extractive industry to collaborative commons. The patient is no longer observed but represented.The Moral DividendIn financial markets, dividends measure productive participation. In moral markets, they measure remembered integrity. Circle introduces a new kind of yield — the dividend of dignity — distributed to all who contribute verified truth to the collective record.It closes the loop between ethics and economy: dignity itself becomes a source of liquidity.The Moral Outcome Value, in the Circle model, is not created by possession or production, but by participation. It is the birthright of those who lend their lived experience to the growth of honest knowledge.Each patient, clinician, and researcher who contributes verifiable truth owns a fraction of its continuing worth. Not by favor, but by design.In this architecture, justice is no longer retrospective — it is programmed into the system.The birth of moral value is the birth of shared ownership in the future of truth.

The Promise and the ProblemArtificial intelligence was meant to transform medicine from intuition to inference — replacing the bias of experience with the precision of pattern recognition. Instead, it has delivered a paradox: astonishing predictive power and diminishing evidentiary value.Regulators hesitate, clinicians distrust, and researchers debate endlessly not whether models “work,” but whether their results can be trusted. The problem is not computation; it is verification. Prediction is mathematics; proof is governance.The Unverifiable MachineTraditional clinical research earns its authority through reproducibility. Trials are documented, data locked, protocols registered. AI models, by contrast, are dynamic — retrained continuously, tuned privately, and often developed on data that cannot legally or technically be shared.The result is epistemic opacity: outputs that cannot be audited, methods that cannot be replicated, and performance claims that evaporate under scrutiny. This is prediction without proof — intelligence unanchored from accountability.Without verifiable provenance, even a correct result is epistemically worthless.What Proof RequiresFor AI to generate clinical evidence, it must satisfy the same principles that govern experimental science:Traceability. Every data point must have a known origin and chain of custody.Reproducibility. Methods must be executable by an independent party.Auditability. Every decision — human or algorithmic — must leave a record.Integrity. The system must ensure that no one can alter inputs or outputs post hoc.Federated Circle Datasets meet these criteria by embedding governance into the data layer itself. The model is not trusted; its process is.Federation as the Proof EngineFederation transforms AI from an act of blind aggregation into a continuous audit. Each institution retains its own data, applies standardized Observational Protocols (OPs), and contributes derivative insights rather than raw information.Because each node’s contribution is independently validated, the resulting global model carries a verifiable lineage. Every prediction becomes not just an output, but an accountable statement backed by a transparent epistemic trail.Circle Datasets thus replace “black box” predictions with chain-of-custody analytics — data and model co-validating one another.The Reproducibility DividendThis design yields what centralized systems never achieved: reproducibility without centralization. An investigator in Boston can re-run a federated analysis using identical protocols applied to distinct patient populations in Berlin or Tokyo — without any data ever leaving its jurisdiction.Results that converge become credible; results that diverge reveal context, not contradiction. The proof lies not in uniformity, but in traceable variation.Medicine regains what it lost in the era of digital opacity: falsifiability.From “Working” to “Valid”An AI model that works is one that predicts correctly. An AI model that is valid is one that predicts correctly for the right reasons, under reproducible conditions, and in a manner that can be independently confirmed. Proof is what separates functionality from reliability. Federated provenance makes that distinction measurable — transforming claims of performance into evidence of integrity. Regulatory ConvergenceGlobal regulators increasingly align around this philosophy. The FDA’s Good Machine Learning Practice framework, the EU AI Act, and the OECD’s AI governance guidelines all converge on one principle: trustworthy AI must be explainable, traceable, and verifiable throughout its lifecycle. Circle Datasets operationalize that principle by making proof a byproduct of process — not an afterthought. The system itself generates the audit trail regulators require.The burden of proof moves from paperwork to architecture. The Moral of VerificationVerification is not bureaucracy; it is ethics made executable. To prove something is to take responsibility for it — to make truth a shared obligation rather than a personal claim. Prediction without proof is speculation; proof without transparency is dogma. Medicine deserves neither. The future of AI will belong to systems that transform computation into conscience — where every prediction carries the weight of evidence, and every insight can stand as testimony.